Headquartered in San Diego, California, Metacrine, Inc. is a clinical-stage biopharmaceutical company specializing in developing therapies for gastrointestinal diseases. Its focus is on developing MET642, which has finished a Phase I clinical study to treat ulcerative colitis. The company was founded in 2014.